Citations

Showing 10 of 108104 citations.

Workplace Violence in the Emergency Department: Case Study on Staff and Law Enforcement Disagreement on Reportable Crimes
McGuire, Sarayna S. , Clements, Casey M. , McGuire, Sarayna S , Mullan, Aidan F.

Mayo Clinic

International Journal of Environmental Research and Public Health | June 2, 2022 | Volume: 19 | Issue: 11 | Pages: 6818

10.3390/ijerph19116818 | PMID 35682399 Get It

Violence in the emergency department (ED) remains underreported. Patient factors are often cited as a source of confusion in determining the culpability of perpetrators and whether to proceed with incident reporting. This study’s objective was to determine how ED staff at one academic medical center perceive certain clinical scenarios and how this compares to local law enforcement officers (LEO). An anonymous survey with 4 scenarios was sent to multidisciplinary ED staff at our academic medical center, as well as local LEO and inquired whether respondents considered any of the scenarios to be reportable as a crime. Chi-square analysis was used for comparison. The study was deemed exempt by the Institutional Review Board. A total of 261 ED staff and 77 LEO completed the survey. Both groups were equally likely to believe that a reportable crime occurred in Scenario 1, where a patient with dementia punches a nurse (LEO: 26.0% vs. ED: 31.4%, p = 0.44), and in Scenario 2, where an intoxicated patient spits at a phlebotomist (LEO: 97.4% vs. ED: 95.0%, p = 0.56). However, the two groups differed in Scenario 3, in which a patient with delirium makes verbal threats to a doctor (LEO: 20.8% vs. ED: 42.9%, p < 0.001), and Scenario 4, in which a patient’s parent throws a chair at a medical student (LEO: 66.2% vs. ED: 81.2%, p = 0.009). As health systems seek to improve workplace safety, it is important to consider the barriers to reporting violent incidents, including staff’s understanding of what acts may constitute reportable violence, as well as LEO understanding of the unique ED environment and patient responsibilities.
First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination
Tella, Sri Harsha , Kommalapati, Anuhya , Mahipal, Amit , Jin, Zhaohui , Mahipal, Amit , Kommalapati, Anuhya , Jin, Zhaohui

Mayo Clinic

Biomedicines | June 2, 2022 | Volume: 10 | Issue: 6 | Pages: 1304

10.3390/biomedicines10061304 | PMID 35740326 Get It

Hepatocellular carcinoma (HCC) is an aggressive malignancy accounting for 90% of primary liver malignancies. Therapeutic options for HCC are primarily based on the baseline functional status, the extent of disease at presentation and the underlying liver function that is clinically evaluated by the Barcelona-Clinic Liver Cancer system and Child–Pugh score. In patients with advanced HCC, the United States Food and Drug Administration (US-FDA) approved systemic therapies include the combination of atezolizumab–bevacizumab, sorafenib, and lenvatinib in the first line setting while cabozantinib, regorafenib, ramucirumab (in patients with alfa-fetoprotein [AFP] > 400 ng/mL), pembrolizumab, nivolumab, and nivolumab-ipilimumab combination are reserved for patients who progressed on sorafenib. European Medical Agency (EMA) approved the use of atezolizumab–bevacizumab, sorafenib, and lenvatinib in the first line setting, while cabozantinib, regorafenib, and ramucirumab (in patients with alfa-fetoprotein [AFP] > 400 ng/mL) are approved for use in patients that progressed on first-line therapy. In the first line setting, sorafenib demonstrated a median overall survival (OS) benefit of 3 months as compared to that of best supportive care in randomized phase III trials, while lenvatinib was shown to be non-inferior to sorafenib. Recently, phase 3 studies with immunotherapeutic agents including atezolizumab plus a bevacizumab combination and tremelimumab plus durvalumab combination demonstrated a better OS and progression free survival (PFS) compared to sorafenib in the first-line setting, making them attractive first-line options in advanced HCC. In this review, we outlined the tumorigenesis and immune landscape of HCC in brief and discussed the role and rationale of combining immunotherapy and anti-VEGF therapy. We further expanded on potential limitations and the future directions of immunotherapy in combination with targeted agents in the management of advanced HCC.
Pilot study of women’s perspectives when abnormal uterine bleeding occurs during perimenopause
DeStephano, Christopher C. , Allyse, Megan , Ridgeway, Jennifer L. , Salinas, Mónica, Spaulding, Aaron , DeStephano, C C , Ridgeway, Jennifer L , Spaulding, Aaron , Allyse, Megan A , Dabrh, Abd Moain Abu , Salinas, M., Sherman, Mark E.

Mayo Clinic

Climacteric | June 2, 2022 | Volume: 25 | Issue: 5 | Pages: 510-515

10.1080/13697137.2022.2073810 | PMID 35652469 Get It

Seizures and epilepsy in multiple sclerosis, aquaporin 4 antibody‐positive neuromyelitis optica spectrum disorder, and myelin oligodendrocyte glycoprotein antibody‐associated disease
Li, Er‐Chuang , Zheng, Yang , Cai, Meng‐Ting , Fang, Gao‐Li , Du, Bing‐Qing , Shen, Chun‐Hong , Zhang, Yinxi , Wu, Long‐Jun , Ding, Meiping , Zhang, Yin-Xi , Ding, Mei-Ping , Wu, Long-Jun , Lai, Qi‐Lun

Mayo Clinic

Epilepsia | June 2, 2022 | Volume: 63 | Issue: 9 | Pages: 2173-2191

10.1111/epi.17315 | PMID 35652436 Get It

AbstractSeizure is one of the manifestations of central nervous system inflammatory demyelinating diseases, which mainly include multiple sclerosis (MS), aquaporin 4 antibody‐positive neuromyelitis optica spectrum disorder (AQP4‐NMOSD), and myelin oligodendrocyte glycoprotein antibody‐associated disease (MOGAD). Acute symptomatic seizures secondary to MS/AQP4‐NMOSD/MOGAD occur in the acute phase of the diseases, and are more frequent in MOGAD. In contrast, recurrent nonprovoked seizures, mainly attributed to autoimmune‐associated epilepsy, occur in the nonacute phase of the diseases. Seizures in MS/AQP4‐NMOSD/MOGAD mostly have a focal onset. MS patients with concomitant systemic infections, earlier onset, and greater disease activity are more likely to have seizures, whereas factors such as greater MS severity, the presence of status epilepticus, and cortical damage indicate a greater risk of developing epilepsy. In MOGAD, cerebral cortical encephalitis and acute disseminated encephalomyelitis (ADEM)‐like phenotypes (predominately ADEM and multiphasic disseminated encephalomyelitis) indicate a greater seizure risk. Multiple relapses with ADEM‐like phenotypes predict epilepsy in pediatrics with MOGAD. Pathophysiologically, acute symptomatic seizures in MS are associated with neuronal hyperexcitability secondary to inflammation and demyelination. Chronic epilepsy in MS is largely due to gliosis, neuronal dysfunction, and synaptic abnormalities. The mainstay of treatment for seizures secondary to MS/AQP4‐NMOSD/MOGAD consists of immunotherapy along with antiseizure medications. This critical review discusses the most‐updated evidence on epidemiology, clinical correlates, and inflammatory mechanisms underlying seizures and epilepsy in MS/AQP4‐NMOSD/MOGAD. Treatment cautions including drug‐drug interactions and the impact of treatments on the diseases are outlined. We also highlight pitfalls and challenges in managing such patients and future research perspectives to address unsolved questions.
The impact of genetic aberrations on response to radium‐223 treatment for castration‐resistant prostate cancer with bone metastases
Liu, Alex J. , Ueberroth, Benjamin E. , Jaeger, Ellen , Ledet, Elisa M. , Tzou, Katherine S., Choo, Richard , Moore, Cassandra N., Ho, Thai H. , Keole, Sameer R., Wong, William W. , Bryce, Alan H. , Singh, Parminder , Ledet, Elisa , Kendi, Ayse T, Tzou, Katherine, Quevedo, Fernando , Wong, William W , Sartor, A Oliver , Bryce, Alan H , Ho, Thai , Jaeger, Ellen B , Singh, Parminder , Kosiorek, Heidi , Kendi, A. Tuba , Quevedo, Fernando , Singh, Parminder Pal , Sartor, Oliver

Mayo Clinic

The Prostate | June 2, 2022 | Volume: 82 | Issue: 12 | Pages: 1202-1209

10.1002/pros.24375 | PMID 35652618 Get It

Abstract Background Radium (Ra)‐223 is an established treatment option for patients with metastatic castrate‐resistant prostate cancer (mCRPC) who have symptomatic bone metastases without soft tissue disease. Studies have indicated genetic aberrations that regulate DNA damage response (DDR) in prostate cancer can increase susceptibility to treatments such as poly ADP‐ribose polymerase inhibitors and platinum‐based therapies. This study aims to evaluate mCRPC response to Ra‐223 stratified by tumor genomics. Methods This is a retrospective study of mCRPC patients who received Ra‐223 and genetic testing within the Mayo Clinic database (Arizona, Florida, and Minnesota) and Tulane Cancer Center. Patient demographics, genetic aberrations, treatment responses in terms of alkaline phosphatase (ALP) and prostate‐specific antigen (PSA), and survival were assessed. Primary end points were ALP and PSA response. Secondary end points were progression‐free survival (PFS) and overall survival (OS) from time of first radium treatment. Results One hundred and twenty‐seven mCRPC patients treated with Ra‐223 had germline and/or somatic genetic sequencing. The median age at time of diagnosis and Ra‐223 treatment was 61.0 and 68.6 years, respectively. Seventy‐nine (62.2%) had Gleason score ≥ 8 at time of diagnosis. 50.4% received prior docetaxel, and 12.6% received prior cabazitaxel. Notable alterations include TP53 (51.7%), BRCA 1/2 (15.0%), PTEN (13.4%), ATM (11.7%), TMPRSS2‐ERG (8.2%), RB deletion (3.4%), and CDK12 (1.9%). There was no significant difference in ALP or PSA response among the different genetic aberrations. Patients with a TMPRSS2‐ERG mutation exhibited a trend toward lower OS 15.4 months (95% confidence interval [CI] 10.0−NR) versus 26.8 months (95% CI 20.9−35.1). Patients with an RB deletion had a lower PFS 6.0 months (95% CI 1.28−NR) versus 9.0 months (95% CI 7.3−11.1) and a lower OS 13.9 months (95% CI 5.2−NR) versus 26.5 months (95% CI 19.8−33.8). Conclusions Among mCRPC patients treated with Ra‐223 at Mayo Clinic and Tulane Cancer Center, we did not find any clear negative predictors of biochemical response or survival to treatment. TMPRSS2‐ERG and RB mutations were associated with a worse OS. Prospective studies and larger sample sizes are needed to determine the impact of genetic aberrations in response to Ra‐223.
Spurious CD34 expression in B‐cell lymphoma due to nonspecific binding to PerCP‐Cy5.5 fluorochrome conjugates: A rare phenomenon and a diagnostic pitfall
Timm, Michael, Howard, Matthew T., Yuan, Ji, Greipp, Patricia T. , Peterson, Jess F. , Roh, Dana J., Olteanu, Horatiu , Ji, Yuan , Timm, Michael M, Horna, Pedro , Olteanu, Horatiu , Peterson, Jess F , Greipp, Patricia T , Yuan, Ji , Shi, Min , Jevremović, Dragan

Mayo Clinic

Cytometry Part B: Clinical Cytometry | June 2, 2022 | Volume: 102 | Issue: 4 | Pages: 326-328

10.1002/cyto.b.22079 | PMID 35652321 Get It

Extended systemic antibiotic prophylaxis in ventricular assist device recipients, an infectious disease perspective
Kusne, Shimon , Irish, William , Arabía, Francisco A. , Arabia, Francisco

Mayo Clinic

Journal of Cardiac Surgery | June 2, 2022 | Volume: 37 | Issue: 7 | Pages: 1819-1823

10.1111/jocs.16487 | PMID 35655403 Get It

Association between Physical Activity and Chronotropic Incompetence in Patients with Complex Congenital Heart Disease
Kim, Hyun Jeong , Yoon, Ja Kyung , Kim, Chul-Ho, Kim, Seong Ho , Franklin, Barry A. , Jae, Sae Young , Kim, Chul-Ho

Mayo Clinic

The Korean Journal of Sports Medicine | June 2, 2022 | Volume: 40 | Issue: 2 | Pages: 86-93

10.5763/kjsm.2022.40.2.86 Get It

Recent Advances in Prostate Cancer (PCa) Diagnostics
Abdelrazek, Ahmad , Mahmoud, Ahmed , Joshi, Vidhu B. , Habeeb, Mohamed Bakry, Ahmed, Mohamed E. , Ghoniem, Khaled, Delgado, Arleen, Khater, Nazih , Kwon, Eugene D., Kendi, A. Tuba , Kendi, A Tuba , Joshi, Vidhu B , Mahmoud, Ahmed M , Ahmed, Mohamed

Mayo Clinic

Uro | June 1, 2022 | Volume: 2 | Issue: 2 | Pages: 109-121

10.3390/uro2020014 Get It

Prostate cancer (PCa), which is among the most prevalent types of cancer in men, is a prominent topic in imaging research. The primary aim of PCa imaging is to acquire more accurate characterizations of the disease. More precise imaging of the local stage progression, early discovery of metastatic cancers, reliable diagnosis of oligometastatic cancer, and optimum treatment response evaluation are areas in which contemporary imaging is quickly improving and developing. Imaging techniques, such as magnetic resonance imaging (MRI) for the whole body and molecular imaging with combined positron emission tomography (PET), computed tomography (CT), and MRI, enable imaging to support and enhance treatment lines in patients with local and advanced PCa. With the availability of multiple imaging modalities for the management of PCa, we aim in this review to offer a multidisciplinary viewpoint on the appropriate function of contemporary imaging in the identification of PCa.
Racial and Ethnic Diversity of U.S. Residency Programs, 2011–2019
Hucko, Lauren , Dominguez, Johanny Lopez , Scott, Nathan L. , Williams, Basil K. , Fountain, Tamara R., Sridhar, Jayanth , Lopez Dominguez, Johanny, Al-khersan, Hasenin , Cavuoto, Kara M.

Mayo Clinic

New England Journal of Medicine | June 1, 2022 | Volume: 386 | Issue: 22 | Pages: 2152-2153

10.1056/nejmc2200107 | PMID 35648712 Get It